SELLAS Life Sciences Group (SLS) Expected to Announce Earnings on Tuesday

Key Points

• Q1 2026 earnings are scheduled before the market opens on Tuesday, May 12, with analysts forecasting EPS of ($0.06) and an earnings call set for Monday, May 11 at 4:00 PM ET.
• In the prior quarter SLS posted ($0.05) EPS, beating estimates by $0.01; the stock recently traded at $4.88 (down 2.9%), carries a market cap of about $900M, and has a 52‑week range of $1.36–$6.14.
• Analyst coverage is mixed—MarketBeat shows a consensus rating of Hold with a $10 average price target (Maxim upgraded to $10, Weiss Ratings reiterated a "sell (d-)")—and institutions own roughly 17.4% of the shares.

SELLAS Life Sciences Group (NASDAQ:SLS - Get Free Report) is projected to release its Q1 2026 results before the market opens on Tuesday, May 12th. Analysts expect SELLAS Life Sciences Group to post earnings of ($0.06) per share for the quarter. Interested persons can check the company's upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Monday, May 11, 2026 at 4:00 PM ET.

SELLAS Life Sciences Group (NASDAQ:SLS - Get Free Report) last released its quarterly earnings data on Thursday, March 19th. The company reported ($0.05) earnings per share for the quarter, topping the consensus estimate of ($0.06) by $0.01.

SELLAS Life Sciences Group Stock Down 2.9%

SLS traded down $0.15 during trading on Tuesday, hitting $4.88. 1,548,646 shares of the company's stock were exchanged, compared to its average volume of 7,393,813. The business's 50 day moving average is $4.90 and its two-hundred day moving average is $3.51. SELLAS Life Sciences Group has a fifty-two week low of $1.36 and a fifty-two week high of $6.14. The stock has a market cap of $899.58 million, a P/E ratio of -19.54 and a beta of 2.24.

Analysts Set New Price Targets

Several research firms have weighed in on SLS. Weiss Ratings restated a "sell (d-)" rating on shares of SELLAS Life Sciences Group in a report on Tuesday, April 21st. Maxim Group upped their price objective on shares of SELLAS Life Sciences Group from $7.00 to $10.00 and gave the stock a "buy" rating in a report on Thursday, March 12th. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Hold" and a consensus price target of $10.00.

Institutional Trading of SELLAS Life Sciences Group

Institutional investors and hedge funds have recently made changes to their positions in the company. The Manufacturers Life Insurance Company raised its holdings in shares of SELLAS Life Sciences Group by 13.6% in the fourth quarter. The Manufacturers Life Insurance Company now owns 38,018 shares of the company's stock valued at $143,000 after purchasing an additional 4,564 shares during the last quarter. Regal Investment Advisors LLC purchased a new stake in shares of SELLAS Life Sciences Group in the fourth quarter valued at about $135,000. Axxcess Wealth Management LLC raised its holdings in shares of SELLAS Life Sciences Group by 121.1% in the fourth quarter. Axxcess Wealth Management LLC now owns 35,370 shares of the company's stock valued at $133,000 after purchasing an additional 19,370 shares during the last quarter. Police & Firemen s Retirement System of New Jersey raised its holdings in shares of SELLAS Life Sciences Group by 48.8% in the fourth quarter. Police & Firemen s Retirement System of New Jersey now owns 34,743 shares of the company's stock valued at $131,000 after purchasing an additional 11,392 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in shares of SELLAS Life Sciences Group in the second quarter valued at about $114,000. Hedge funds and other institutional investors own 17.38% of the company's stock.

About SELLAS Life Sciences Group

SELLAS Life Sciences Group, Inc is a clinical-stage biopharmaceutical company focused on the development of active cellular immunotherapies for cancer. Headquartered in Waltham, Massachusetts, SELLAS specializes in targeting the Wilms' tumor 1 (WT1) antigen, a protein commonly overexpressed in a range of hematologic and solid tumors. Since its founding, the company has built a pipeline around the use of peptide-based vaccines designed to train the patient's own immune system to recognize and attack WT1-positive cancer cells.

The company's lead product candidate, galinpepimut-S (GPS), is an investigational multi-peptide vaccine directed against WT1.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.